申请人:Pfizer Inc.
公开号:US20030195205A1
公开(公告)日:2003-10-16
The invention relates to PDE9 inhibitors for treating cardiovascular disorders. Preferred PDE9 inhibitors are compounds of formula I wherein R
1
is H or C
1-6
alkyl, wherein R
1
is attached to either N
1
or N
2
; R
2
is C
1-6
alkyl optionally substituted by hydroxy or alkoxy; C
3-7
cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het1 or Ar
1
; R
3
is C
1-6
alkyl optionally substituted by 1 or 2 groups independently selected from: Ar
2
; C
3-7
cycloalkyl optionally substituted by C
1-6
alkyl; OAr
2
; SAr
2
; NHC(O)C
1-6
alkyl; het
2
; xanthene; and naphthalene.
1
该发明涉及用于治疗心血管疾病的PDE9抑制剂。首选的PDE9抑制剂是具有以下结构的化合物,其中R1是H或C1-6烷基,其中R1连接到N1或N2中的任一者;R2是C1-6烷基,可选择地被羟基或烷氧基取代;C3-7环烷基,可选择地被烷基、羟基或烷氧基取代;饱和的5-6成员杂环,可选择地被烷基、羟基或烷氧基取代;het1或Ar1;R3是C1-6烷基,可选择地被从Ar2中独立选择的1或2个基团取代;C3-7环烷基,可选择地被C1-6烷基取代;OAr2;SAr2;NHC(O)C1-6烷基;het2;黄酮;和萘。